Back in 2021, Barbara Mullin of Patterson Belknap Webb & Tyler landed Litigator of the Week honors after helping Johnson & Johnson subsidiary Janssen fend off a challenge to the patent behind Invega Sustenna. The blockbuster injectable antipsychotic drug, which is used to treat schizophrenia and related disorders, generates more than $2 billion in annual sales in the U.S. The firm’s 2021 win followed an 11-day Zoom bench trial before U.S. District Judge Claire Cecchi in New Jersey. It partially stood up on appeal, but the Federal Circuit remanded the obviousness challenge brought by generic makers Teva and Mylan. After a team led by Mullin and colleagues Aron Fischer and Andrew Cohen represented Janssen back at the district court, Cecchi sided with the company again finding Teva hadn’t proven its invalidity-via-obviousness case in a 62-page decision made public this week. The Patterson Belknap team includes Lachlan Campbell-Verduyn, Jay Cho, Zhiqiang Liu, Meghan Larywon and Collin Hong.